medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 4

<< Back Next >>

Medicina & Laboratorio 2022; 26 (4)

Seroprevalence of transmissible infections in blood donors

Machado-Rodríguez D, Chiriboga-Ponce RF

Language: Spanish
References: 18
Page: 353-364
PDF size: 98.17 Kb.


ABSTRACT

Introduction. Transfusion safety is the primary objective of blood banks, however one of the adverse reactions to blood transfusion are the transfusion transmissible infections (TTIs). Knowledge of the prevalence of these infections was of particular interest in this study where we determined their frequency, co-infection and relationship with the type of donors admitted. Methodology. Retrospective observational study during 2017 and 2018, in which all blood donor records containing demographic data and results of the country's (Ecuador) mandatory serological markers of both serological and molecular tests were included. Permission was obtained from the data custodian and the Human Research Bioethics Subcommittee. Descriptive and inferential statistics were used for data analysis. Results. A prevalence of 3,18% of reactive results to one or more TTIs was determined, the most prevalent age range was 29 to 40 years, 89.8% were compensatory donors and 90% of them were reactive to one or more TTIs. The anti- core serological marker of the hepatitis B virus (anti-HBc) was the most prevalent, followed by syphilis and hepatitis C antibodies. Syphilis and hepatitis B were identified as the most prevalent coinfection. The correlation between the results obtained in the serological and molecular tests was determined to be different and statistically significant (x2=26.9; p=0.000). Conclusion. TTIs in blood banks are a latent risk, so it is necessary to know the epidemiological variations that exist in every population. Knowledge of the prevalence of TTIs in blood donors facilitates new donor selection strategies that guarantee the best possible safety in transfusions. In addition, the methodology used must always be verified and the established quality system must be permanently monitored.


REFERENCES

  1. Noubiap JJ, Joko WY, Nansseu JR, Tene UG,Siaka C. Sero-epidemiology of human immunodeficiencyvirus, hepatitis B and C viruses,and syphilis infections among first-time blooddonors in Edéa, Cameroon. Int J Infect Dis 2013;17:e832-837. https://doi.org/10.1016/j.ijid.2012.12.007.

  2. World Health Organization (WHO). Disponibilidady seguridad de la sangre. Ginebra, Suiza:WHO; 2022. Acceso 20 de junio de 2022.Disponible en https://www.who.int/es/newsroom/fact-sheets/detail/blood-safety-and-availability.

  3. Tafesse TB, Gebru AA, Gobalee S, Belay GD,Belew MT, Ataro D, et al. Seroprevalence anddiagnosis of HIV, HBV, HCV and syphilis infectionsamong blood donors. Hum Antibodies2017;25:39-55. https://doi.org/10.3233/hab-160304.

  4. Rebouças K, Narici FM, Santos-Junior MN,Neres NSM, Oliveira MV, Souza CL. Seroprevalenceof transfusion-transmissible infectiousdiseases at a hemotherapy servicelocated in southwest Bahia, Brazil. HematolTransfus Cell Ther 2019;41:324-328. https://doi.org/10.1016/j.htct.2019.03.007.

  5. Ramos VF, Ferraz FN. Perfil epidemiológicodos doadores de sangue do hemonúcleo deCampo Mourão-PR no ano de 2008. SaBios2010;5:14-21.

  6. Rodriguez DM, Lara GM, Lazzarotto AR, MichelimL, Fracasso J, Lovate R, et al. Prevalênciade marcadores sorológicos no Banco deSangue de Caxias do Sul, RS. Rev Panam Infec2008;10:32–35.

  7. Gómez LA, Peñuela O, Higuera F. Prevalenceof antibodies against transfusion-transmissibleinfections (TTI) in blood donors from the Colombianeastern region. Clin Lab 2014;60:869-871.https://doi.org/10.7754/clin.lab.2013.130703.

  8. Stramer SL, Zou S, Notari EP, Foster GA,Krysztof DE, Musavi F, et al. Blood donationscreening for hepatitis B virus markers in theera of nucleic acid testing: are all tests of value?Transfusion 2012;52:440-446. https://doi.org/10.1111/j.1537-2995.2011.03283.x.

  9. Oliveira VM, Verdasca IC, Monteiro MC. Detecçãode sífilis por ensaios de ELISA e VDRLem doadores de sangue do Hemonúcleode Guarapuava, Estado do Paraná. Rev SocBras Med Trop 2008;41:428-430. https://doi.org/10.1590/s0037-86822008000400023.

  10. Guerrero-García JJ, Zúñiga-Magaña AG, Barrera-De León JC, Magaña-Duarte R, Ortuño-Sahagún D. Retrospective study of the seroprevalenceof HIV, HCV, and HBV in blood donorsat a blood bank of Western Mexico. Pathogens2021;10:878 https://doi.org/10.3390/pathogens10070878.

  11. Mangano VD, Prato M, Marvelli A, MoscatoG, Bruschi F. Screening of at-risk blood donorsfor Chagas disease in non-endemic countries:Lessons from a 2-year experience in Tuscany,Italy. Transfus Med 2021;31:63-68. https://doi.org/10.1111/tme.12741.

  12. Jary A, Dienta S, Leducq V, Le Hingrat Q,Cisse M, Diarra AB, et al. Seroprevalenceand risk factors for HIV, HCV, HBV and syphilisamong blood donors in Mali. BMC InfectDis 2019;19:1064. https://doi.org/10.1186/s12879-019-4699-3.

  13. Karabaev BB, Beisheeva NJ, SatybaldievaAB, Ismailova AD, Pessler F, Akmatov MK.Seroprevalence of hepatitis B, hepatitis C, humanimmunodeficiency virus, Treponema pallidum,and co-infections among blood donorsin Kyrgyzstan: a retrospective analysis (2013-2015). Infect Dis Poverty 2017;6:45. https://doi.org/10.1186/s40249-017-0255-9.

  14. Álvarez-Carrasco RI. Interpretación de laspruebas usadas para diagnosticar la infecciónpor virus de la inmunodeficiencia humana. ActaMed Peru 2017;34:309-316.

  15. Rave-Zuluaga DY, Rendón-Castrillón LE,Calvo-Betancur VD. Donante voluntario y dereposición sero-reactividad en el municipio deRionegro Antioquia. Univ Salud 2011;13:43-49.

  16. Rodríguez-Leiva RR. Seroprevalencia de marcadorespara infecciones transmisibles portransfusión en donantes de un hospital de referencianacional de Paraguay, 2016. Mem InstInvestig Cienc Salud 2020;18:61-68.

  17. Datta S, Khillan K, Ranjan V, Wattal C. Nucleicacid amplification test: Bridging the gapin blood safety & re-evaluation of blood screeningfor cryptic transfusion-transmitted infectionamong Indian donors. Indian J Med Res2019;149:389-395. https://doi.org/10.4103/ijmr.IJMR_1340_17.

  18. Eusebio-Ponce E, Candel FJ, Paulino-RamirezR, Serrano-García I, Anguita E. Seroprevalenceand trends of HTLV-1/2 among blood donorsof Santo Domingo, Dominican Republic,2012-2017. Rev Esp Quimioter 2021;34:44-50.https://doi.org/10.37201/req/117.2020




2020     |     www.medigraphic.com